Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1805549 | 0.85 | MAPK1 (0.55) | CA2KDM4EPOLBGAACA12 | |
| SCHEMBL7141964 | 0.85 | POLB (0.49) | CA2KDM4EPOLBGAACA12 | |
| SCHEMBL1048077 | 0.85 | CA2 (0.55) | CA2KDM4EPOLBCA12CA1 | |
| SCHEMBL15746904 | 0.85 | POLB (0.54) | KDM4EPOLBGAATSHRLMNA | |
| SCHEMBL1805547 | 0.84 | POLB (0.48) | CA2KDM4EPOLBGAACA12 | |
| SCHEMBL11183735 | 0.84 | POLB (0.48) | CA2KDM4EPOLBGAACA12 | |
| SCHEMBL8862312 | 0.83 | KDM4E (0.62) | KDM4EPOLBGAATSHRLMNA | |
| SCHEMBL29543150 | 0.83 | KDM4E (0.62) | KDM4EPOLBGAATSHRLMNA | |
| SCHEMBL35247 | 0.83 | LMNA (0.66) | KDM4EPOLBGAATSHRLMNA | |
| SCHEMBL7824801 | 0.82 | CA2 (0.55) | CA2KDM4EPOLBGAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8211221-B2 | Colorant compound and ink including the colorant compound | CANON KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100089284-A1 | COLORANT COMPOUND AND INK INCLUDING THE COLORANT COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2010-04-15 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| EP-0102195-A2 | Substituted aza bicycloalkyl derivatives with dopamine antagonist activity | BEECHAM GROUP PLC (GB) | 1984-03-07 | — | — | EP | disclosed |
| EP-0023964-B1 | PHENYLIMINOTHIAZOLINE DERIVATIVES, THEIR PREPARATION AND INTERMEDIATES THEREFOR, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR PRODUCTION | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-16 | — | — | EP | disclosed |
| US-4346088-A | ANTILIPEMICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-08-24 | — | — | US | disclosed |
| EP-0023964-A1 | Phenyliminothiazoline derivatives, their preparation and intermediates therefor, pharmaceutical preparations containing them and their production | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | CA2 2838/4885KDM4E 1862/4885POLB 1884/4885 |
| US-20100089284-A1 | COLORANT COMPOUND AND INK INCLUDING THE COLORANT COMPOUND | CDKL5, RB1, CYP3A5 | CA2 1787/4885KDM4E 1200/4885POLB 4739/4885 |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | CA2 4267/4885KDM4E 4644/4885POLB 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.